Media Articles Related to Glycopyrrolate
COPD: Sunovion Pharmaceuticals Inc. announces positive results from two Phase 3 clinical studies evaluating SUN-101/eFlow
Source: Respiratory / Asthma News From Medical News Today [2016.04.28]
Sunovion Pharmaceuticals Inc. (Sunovion) has announced positive results from the Phase 3 clinical trial program for SUN-101 (glycopyrrolate), a nebulized long-acting muscarinic antagonist (LAMA)...
FDA Clears Bevespi Aerosphere for COPD
Source: Medscape Family Medicine Headlines [2016.04.27]
Bevespi combines glycopyrrolate and formoterol fumarate in a pressurized metered-dose inhaler, using novel technology that promises more uniform drug distribution, according to the company.
Published Studies Related to Glycopyrrolate
Prophylactic glycopyrrolate reduces hypotensive responses in elderly patients
during spinal anesthesia: a randomized controlled trial. 
responses in elderly patients undergoing spinal anesthesia... CONCLUSION: Prophylactic intramuscular glycopyrrolate reduced the occurrence and
Prophylactic glycopyrrolate prevents bradycardia after spinal anesthesia for Cesarean section: a randomized, double-blinded, placebo-controlled prospective trial with heart rate variability correlation. [2011.08]
STUDY OBJECTIVE: To determine if prophylactic glycopyrrolate prevents bradycardia after spinal anesthesia... CONCLUSION: Bradycardia after spinal anesthesia occurs commonly. Prophylactic glycopyrrolate may prevent the bradycardia, but not necessarily the hypotension. Copyright (c) 2011 Elsevier Inc. All rights reserved.
Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study. [2010.06]
BACKGROUND: Clozapine-induced sialorrhea (CIS) is a subjective distressing adverse effect and occurs in 31%-57% of schizophrenic patients receiving clozapine therapy. Current pharmacotherapy on CIS has focused on anticholinergic agents, even though they may impair cognitive function. Previous case reports have suggested the benefit of glycopyrrolate or biperiden in treating this condition, but no randomized controlled trial has provided evidence. The objective of our study was to evaluate the efficacy and impact on cognition of glycopyrrolate and biperiden treatments for schizophrenic patients suffering from CIS... CONCLUSION: We provide evidence, for the first time, of the efficacy of glycopyrrolate and biperiden in the treatment of CIS. Furthermore, glycopyrrolate displays less impact on cognitive function. Consequently, glycopyrrolate can become a valid option for treating CIS. Observations from our study serve as a springboard for additional large-scale prospective trials. Copyright (c) 2010 Elsevier B.V. All rights reserved.
Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. [2010.04.13]
BACKGROUND: Sialorrhea affects approximately 75% of patients with Parkinson disease (PD). Sialorrhea is often treated with anticholinergics, but central side effects limit their usefulness. Glycopyrrolate (glycopyrronium bromide) is an anticholinergic drug with a quaternary ammonium structure not able to cross the blood-brain barrier in considerable amounts. Therefore, glycopyrrolate exhibits minimal central side effects, which may be an advantage in patients with PD, of whom a significant portion already experience cognitive deficits. OBJECTIVE: To determine the efficacy and safety of glycopyrrolate in the treatment of sialorrhea in patients with PD... CONCLUSIONS: Oral glycopyrrolate 1 mg 3 times daily is an effective and safe therapy for sialorrhea in Parkinson disease. Classification of evidence: This study provides Class I evidence that glycopyrrolate 1 mg 3 times daily is more effective than placebo in reducing sialorrhea in patients with Parkinson disease during a 4-week study.
Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind,
crossover trial. 
treatment of sialorrhea in patients with PD... CONCLUSIONS: Oral glycopyrrolate 1 mg 3 times daily is an effective and safe
Clinical Trials Related to Glycopyrrolate
Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation [Completed]
The purpose of this study is to determine if the antisialagogues (anti-salivary agents),
Atropine and Glycopyrrolate, are effective in reducing hypersalivation when sedating
patients with Ketamine for procedural sedation in the emergency department or abscess
clinic. The investigators will measure salivary flow rate by collecting oral secretions by
oral suctioning over a 30 minute time period starting with the administration of Ketamine.
The investigators hypothesize that patients who receive either atropine or glycopyrrolate
will have fewer oral secretions than patients who receive placebo.
Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Glycopyrrolate (AIDES-G) [Recruiting]
The study consists of measurement of antidepressant-induced excessive sweating and its
treatment with an experimental medication, glycopyrrolate (approved to treat ulcers), which
will be added to the antidepressant. This is an open-label study (no placebo group or
concealment of the nature of the treatment) that will last 8 weeks, including two weeks of
baseline measurement without treatment with the study medication followed by six weeks of
treatment with the study medication. The study is pilot study by Dr. Rajnish Mago that is
based on the hypothesis that glycopyrrolate will be effective in reducing the severity of
excessive sweating caused by antidepressant treatment, and will have minimal side-effects.
Study is to Determine the Extent of Pulmonary Absorption of Glycopyrrolate Following Dosing Via eFlow Nebulizer and Seebri« Breezhaler« With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (GOLDEN 7) [Not yet recruiting]
The purpose of this research study is to determine the extent of pulmonary absorption of
glycopyrrolate following dosing via eFlow nebulizer and Seebri« Breezhaler« with and without
activated charcoal in subjects with moderate to severe chronic obstructive pulmonary disease
Dose Ranging Study of Glycopyrronium Bromide in Patients With Moderate or Severe Chronic Obstructive Pulmonary Disease [Completed]
This is an investigation of the beneficial effects, tolerability and safety of a range of
single doses of orally inhaled glycopyrronium bromide (PSX1002GB pMDI) in male and female
patients with moderate or severe chronic obstructive pulmonary disease (COPD). COPD is a
long term and progressive disease of the lungs, generally caused by cigarette smoking, but
other factors may be involved. Glycopyrronium bromide (GB) appears to be particularly useful
in dilating the constricted airways of such patients, with a duration of action variously
described as being between 12 and 24 hours.
This study will investigate how well tolerated and safe this medication is at a range of
doses. It will also help in the selection of a suitable dose for larger and repeat dose
studies, based on measures of lung response. It will also help to determine how often the
medication should be given; twice daily, or once daily.
Up to 40 patients will be enrolled into the study, ranging in age from 40 to 75 years of
age. Patients will be medically assessed before participation to ensure their suitability.
The study will take place in one centre in the UK over five sessions; at each session one
dose (2 puffs) of GB or one dose (2 puffs) of placebo will be administered from a simple
inhaler device. Neither staff nor patients will know which dose, or if placebo, is being
taken. Lung function will be measured for up to 26 hours after the administration of each
dose using standard spirometry equipment. Blood samples will be taken over a 24-hour period
to check the blood levels of GB. There will be a period of about a week between each dosing
session. Patients will be medically reviewed after the study to confirm that no untoward
effects are present.
Effect of Glycopyrrolate and Atropine on Catheter-Related Bladder Discomfort [Recruiting]
We want to evaluate the efficacy of the glycopyrrolate and atropine for the prevention of
catheter-related bladder discomfort.
Reports of Suspected Glycopyrrolate Side Effects
Drug Interaction (6),
Atrioventricular Dissociation (5),
Medication Error (2),
Circumstance or Information Capable of Leading TO Medication Error (2),
Autonomic Nervous System Imbalance (2),
Supraventricular Tachycardia (2),
Atrial Fibrillation (2),
Product Substitution Issue (1),
Anaphylactic Reaction (1),
Tachycardia (1), more >>